We analyzed 368 chronic lymphocytic leukemia patients who underwent allogeneic hematopoietic stem cell transplantation reported to the EBMT registry between 1995 and 2007. There were 198 human leukocyte antigen (HLA)-identical siblings; among unrelated transplants, 31 were well matched in high resolution ('well matched' unrelated donor, WMUD), and 139 were mismatched (MM), including 30 matched in low resolution; 266 patients (72%) received reduced-intensity conditioning and 102 (28%) received standard. According to the EBMT risk score, 11% were in scores 1-3, 23% in score 4, 40% in score 5, 22% in score 6 and 4% in score 7. There was no difference in overall survival (OS) at 5 years between HLA-identical siblings (55% (48-64)) and WMUD (59% (41-84)), P ¼ 0.82. In contrast, OS was significantly worse for MM (37% (29-48) P ¼ 0.005) due to a significant excess of transplant-related mortality. Also OS worsened significantly when EBMT risk score increased. HLA matching had no significant impact on relapse (siblings: 24% (21-27); WMUD: 35% (26-44), P ¼ 0.11 and MM: 21% (18-24), P ¼ 0.81); alemtuzumab T-cell depletion and stem cell source (peripheral blood) were associated with an increased risk. Our findings support the use of WMUD as equivalent alternative to HLA-matched sibling donors for allogeneic HSCT in CLL, and justify the application of EBMT risk score in this disease.
Introduction
Chronic lymphocytic leukemia (CLL) remains incurable with standard therapies. Most patients with CLL have an indolent clinical course, but the development of new prognostic markers has enabled us to identify patients with aggressive disease and of poor prognosis. [1] [2] [3] [4] Apart from the clinical course, poor prognosis can be predicted by the presence of unfavorable cytogenetics, an unmutated status of the variable region of the immunoglobulin heavy-chain gene, or expression of the ZAP70 gene product. [1] [2] [3] [4] Younger patients with adverse risk factors are therefore candidates for clinical trials exploring hematopoietic stem cell transplantation (HSCT). 5 Autologous HSCT is feasible and has low treatment-related mortality (TRM), but it is not curative. 6 Myeloablative allogeneic SCT (allo-HSCT) is associated with high TRM and few late relapses in CLL, 7 but is applicable to only a small number of patients. Recently, the major focus of transplantation in CLL has been with reducedintensity conditioning (RIC) allo-HSCT, which is applicable to the more elderly patient population and which attempts to exploit the graft-versus-leukemia effect that exists in CLL. [7] [8] [9] [10] [11] Only 30% of patients in need of allo-HSCT will have a suitable human leukocyte antigen (HLA)-matched family member, and in the remainder an unrelated donor (UD) may be sought. 12 Although studies on large homogeneous samples in standard-risk hematopoietic malignancy (that is, chronic myeloid leukemia) suggest inferior results for UD compared with sibling transplants, 13, 14 disadvantages of UD have not emerged in the trials on RIC allo-HSCT in CLL performed to date. 9, [15] [16] [17] [18] [19] However, analyses on donor effects in CLL have been hampered by small patient numbers, and generally disregarded the potentially important impact of HLA class-I allele and HLA C mismatch. 20, 21 Weisdorf and co-workers 22 have proposed a classification for retrospectively assigning UD-recipient pairs to HLA-matching clusters, despite incomplete availability of class-I allele and HLA C typing results,thereby discriminating wellmatched, partially matched and mismatched pairs. This system enables the analysis of the impact of HLA mismatch in registry samples with incomplete HLA typing results.
In this study, our main objective was to evaluate the impact of HLA matching according to current standards on the different outcomes.
Patients and methods

Patients
This retrospective analysis was conducted on CLL patients who underwent an allo-HSCT reported to the EBMT registry between the years 1995 and 2007. In our analysis, we included patients from EBMT centers performing allo-HSCT from both related and UDs for CLL and who had full information available on HLA typing results, as required for the purposes of this study. There were 368 patients, 278 males (76%) and 90 females with a median age of 53 years . Forty-one patients (11%) had received a previous autologous HSCT. At transplant, 293 (93%) among 316 evaluable patients had a good performance score 23 (PS p1), 43 (12%) patients were in complete remission, 159 (46%) in partial remission (PR), 43 (13%) in stable disease and 103 (29%) in progressive disease among 348 evaluable patients. Patient characteristics and treatment modalities are described in Table 1 .
Conditioning regimens
Conditioning regimens were classified as proposed by a recent Center for International Blood and Marrow Research (CIBMTR) workshop. 24 Any regimen that included (a) total body irradiation of p500 cGy as a single fraction or p800 cGy if fractionated, (b) p9 mg/kg of oral busulfan (or intravenous equivalent), (c) p140 mg/m 2 of melphalan, (d) o10 mg/kg of thiotepa, (e) the BEAM regimen (carmustine, etoposide, cytarabine and melphalan) was considered as RIC. Two hundred and sixty-six patients received RIC and 102 myeloablative conditioning. There were 82 patients who received in vivo T-cell depletion with alemtuzumab as part of their conditioning.
HLA matching
Full information on HLA typing had to be available for all participating patients either in the registry or by request from the center, and was carefully analyzed to assess the matching degree between recipient and donor. HLA typing was evaluated Impact of HLA matching in Allo-HSCT for CLL M Michallet et al for allele and antigen level mismatches across four loci HLA-A, -B, -C and DRB1. In the majority of cases (83%), HLA typing results were available on a molecular level (high resolution).
Besides the HLA-identical sibling group (n ¼ 198), UDs were clustered according to the Weisdorf classification. 22 Thirty-one patients with at least 8/8 HLA matched in high resolution on HLA-A, B, C and DRB1 corresponded to the 'well matched' unrelated donor (WMUD) group, and 139 patients corresponded to the 'partially matched' or 'mismatched' UD groups of the Weisdorf system, including 30 patients who were 'matched' in low resolution (6/6 HLA low resolution matched on HLA-A, B and DRB1 (C unknown)); and a group with at least one allele mismatched on HLA-A, B, C or DRB1 in high resolution (MMUD) (n ¼ 109). For the purposes of this study, partially matched and mismatched HLA groups were considered together as mismatched (MM) UDs.
Transplantation procedure
The HSCT source was peripheral blood stem cells (PBSCs) for 312 patients (85%) and bone marrow for 56 patients (15%). Patients received transplants from 198 HLA siblings (54%) and 170 UDs (46%). There were 134 (36%) sex mismatched (89 F/M and 45 M/F), 150 pairs (41%) had an ABO incompatibility (61 minor, 89 major) and for cytomegalovirus: 78 pairs were negative, 146 positive and 111 mixed. The median interval between diagnosis and transplantation was 53 months (3-308). The GVHD prophylaxis, known in 306 cases, consisted of ciclosporine A (CsA) alone in 92 (30%) patients, combination of CsA and methotrexate in 119 (39%) patients and combination of CsA and mycophenolate mofetil in 58 (19%) patients. Thirty seven (12%) patients received other combinations.
EBMT risk score
We have classified our patients according to the EBMT risk score 25, 26 that uses the 5 pretransplant risk factors: age of the patient, disease status, time from diagnosis to transplant, donor type, and donor-recipient sex combination with 0 to 1 or 2 points for each factor. Age was categorized as o20 years (0), 20 to 40 years (1) and 440 years (2) . For disease status, we applied a score (0) for patients in complete remission at transplantation, (1) for patients in PR and (2) for patients in less than PR. Time from diagnosis to transplant was categorized into p12 months (0) and 412 months (1). Donor type separated HLA-identical sibling transplants (0) from UD transplants (1). Donor-recipient sex combination separated all others (0) from the male recipient with a female donor (1). Hence, the score ranged from 0 to a maximum of 7 risk points. Among 346 evaluable patients with full EBMT score information available, we found three patients (1%) in score 1, seven (2%) in score 2, 29 (8%) in score 3, 81 (23%) in score 4, 137 (40%) in score 5, 75 (22%) in score 6 and 14 (4%) in score 7. EBMT risk score details are described in Table 2 .
Statistical analysis
Kaplan Meier product-limit estimates were used to assess the probability of overall survival (OS). 27 Cumulative incidences of TRM, relapse, and acute and chronic GVHD were assessed Impact of HLA matching in Allo-HSCT for CLL M Michallet et al within a competing risk framework. TRM was defined as death occurring prior to CLL relapse or progression after transplant; death from relapse was considered as a competing risk. Acute and chronic GVHD were considered as one time-varying event.
Multivariate analysis was performed using a Cox proportional hazard model 28 including pre-transplantation variables: patient's age, disease status at transplantation, performance score (PS), HSCT source, sex matching (Mr-Fd vs other), ABO compatibility, cytomegalovirus matching (Pos-Neg vs other), alemtuzumab in vivo T-cell depletion,, conditioning regimen, year of transplant (after 2001 vs p2001) and different HLA groups. All tests were two-tailed and considered significant when Po0.05. All statistical analyses were carried out using R statistical software (version 2.9.2).
Results
Engraftment and graft-versus-host disease
After transplantation, 349 (95%) patients engrafted. There were 199 patients who developed acute graft-versus-host disease (GVHD) (grade I: 74, grade II: 79, grade III: 29 and grade IV: 17) and 168 who had chronic GVHD (70 limited and 98 extensive). The cumulative incidence of acute GVHD for the total population was 31% for grade II-IV and 12% for grade III-IV (siblings: 27 and 11%; WMUD: 39 and 6%; MM: 34 and 14% for grade II-IV and grade III-IV, respectively). The cumulative incidence of overall and extensive chronic GVHD 1 year after transplant was 35% (32.5-37.5) and 21% (19) (20) (21) (22) (23) , respectively, for the total population (siblings: 33 and 19%; WMUD: 45 and 26%; MM: 35 and 22%). Significant differences between the three HLA groups with regard to acute and chronic GVHD were not observed.
Overall survival, relapse incidence and TRM
After a median follow-up of 46 (1-157) months, the probability of 3-and 5-year OS for the total population was 56% (51-61) and 49% (43-55), respectively. We found a highly significant difference in terms of OS between siblings and WMUD versus the MM group (siblings vs WMUD, P ¼ 0.82; siblings vs MM, Po0.001 and WMUD vs MM, P ¼ 0.07) (OS at 3 and 5 years: siblings: 64% (57-71) and 55% (48-64); WMUD: 59% (41-84) (the same at 3 and 5 years); MM: 43% (35-52) and 37% (29-48), respectively) ( Figure 1a ). Of note, within the MM group a significant OS difference between the 109 truly mismatched patients and the 30 patients who were 6/6 matched at low resolution was not observed. In contrast, disease status at transplantation had a highly significant impact on OS (5-year OS: 79, 54 and 38% for patients in complete remission, PR and less than PR, respectively (Po0.001)) (Figure 1b) . When examined according to the EBMT risk score, we failed to detect any significant difference between the few patients with score 1, 2 or 3, which led us to pool those patients. There was a significant difference in OS at 5 years between patients with score 1-3 and patients having a higher score (score 4: hazard ratio (HR) ¼ 3.37 (1.3-8.7), P ¼ 0.012; score 5: HR ¼ 4.97 (2.0-12.3), Po0.001; score 6-7: HR ¼ 7.02 (2.8-17.6), Po0.001) (Figure 2 ).
With regard to relapse incidence, HLA matching had no significant impact on relapse (siblings: 24% (21-27); WMUD: 35% (26-44) (HR ¼ 1.68 (0.89-3.18), P ¼ 0.11) and MM: 21% (18-24) (HR ¼ 1.06 (0.67-1.68), P ¼ 0.81)) (Figure 3a) .
When TRM was investigated according to HLA matching, this was significantly increased with MM (HR ¼ 1.86 (1.27-2.73), (Figure 3b ). The predominant TRM causes were infection (10% for siblings vs 19% for MM (P ¼ 0.03)), GVHD (6% for siblings vs 11% for MM (P ¼ 0.13)) and other complications (hemorrhage, multiorgan failure, heart failure) (2.5% for siblings vs 2% for MM (P ¼ 0.9)).
Multivariate analysis
We used multivariate analysis using Cox modeling to study the impact of HLA group adjusted for age, pretransplant disease status, PS, HSC source, ABO compatibility, cytomegalovirus matching, in vivo T-cell depletion, conditioning and year of transplant. Although in comparison with siblings the MM patients had a significantly inferior outcome in terms of OS (HR 1.67 (95% confidence interval 1.16-2.4); P ¼ 0.0054) and TRM (HR 1.98 (95% confidence interval 1.19-3.31); P ¼ 0.0087), a significant difference between WMUD and siblings did not become obvious for any end point with HRs between 0.86 and 0.97 in favor of WMUD (Table 3) . Besides MM HLA group, increasing age and less than PR at HSCT adversely affected OS, TRM and also progression-free survival. With regard to relapse, alemtuzumab T-cell depletion and stem cell source (peripheral blood) were associated with an increased risk.
Discussion
With the development of worldwide registries, the increasing potential of UDs and the availability of new conditioning regimens, especially for older patients, the number of allo-HSCT for CLL has considerably increased during the past 10 years. 29 Despite significant progress in conventional treatment due to the development of new agents, allo-HSCT remains the only potentially curative therapy in CLL, and the only one providing long-term control of poor-risk disease. 29 However, important questions are still unresolved, including the impact of donor source and match on the allo-HSCT outcome in CLL.
With the introduction of high-resolution HLA typing and recognition of the immunogenetic relevance of the HLA C locus, a number of studies have assessed the impact of modern HLA matching on patient outcomes in allo-HSCT standard indications. 20, 21, [30] [31] [32] Similar large-scale analyses for patients with CLL are lacking. All information available for the effect of using UD in CLL comes from CLL-specific prospective studies with relatively limited patient numbers, in which donor impact was investigated as secondary objective. Although one small study regarding myeloablative allo-HSCT from HLA siblings and UD showed an OS significantly better for siblings compared with UD, 33 a significantly unfavorable effect of UD could not be found in any of the prospective RIC studies published to date. 7, 9, 17, 19, 34 However, only one of these analyses addressed Impact of HLA matching in Allo-HSCT for CLL M Michallet et al the influence of HLA mismatch according to the current HLA typing standards as a secondary objective in a small sample size, and found no differences between well and partially matched UDs in comparison with sibling donors. 34 Of note, all UDs in that study received ATG. 34 In this report, our main objective was to evaluate the impact of HLA matching degree on different patient outcomes based on much larger patient numbers. We have shown, for the first time, that there is no difference between HLA-matched siblings and well-matched UDs in terms of OS and TRM. In contrast, outcome for both end points was significantly worse for partially matched or mismatched UDs due to the significantly higher incidence of TRM in these groups.
With a continuously growing donor pool and ongoing refinements of HLA typing methodology, it is probable that the proportion of WMUD will increase steadily. Although the results for MMUD transplants are inferior, the 5-year OS of 40% observed with MMUD here still might represent a pronounced prognostic improvement for certain patient populations with high-risk CLL. Therefore, the specific disease risk and the EBMT score rather than the donor source alone should be considered to guide the decision for or against HSCT in each individual patient.
As the EMBT risk score was originally validated across different hematological malignancies, we have applied it for the first time specifically on patients with CLL and studied the OS and TRM outcomes. The EBMT score had significant prognostic influence despite the fact that low scores were underrepresented due to the lack of very young patients and those with a short interval from diagnosis to transplant in the CLL population. Although this needs to be reproduced in other cohorts, the EBMT score may be a useful contributory factor when defining indications of allo-HSCT in CLL.
In conclusion, our findings support the use of well-matched UDs, as well as HLA-matched sibling donors within the context of the European consensus 35 for indications for allo-HSCT in CLL. However, as even mismatched donor transplants showed a 5-year OS of 40%, a MMUD might be a reasonable alternative if an HLA-identical sibling or a well-matched UD is not available in clinical trials on allo-HSCT for poor-risk CLL.
